Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Bank of America
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Friday, Marketbeat.com reports. The firm currently has a $42.00 target price on the stock. Bank of America‘s price target suggests a potential upside of 89.10% […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Friday, Marketbeat.com reports. The firm currently has a $42.00 target price on the stock. Bank of America‘s price target suggests a potential upside of 89.10% […]
